FDA Pediatric HIV Update: ViiV’s Tivicay PD (dolutegravir dispersible tablets) is now approved for eligible infants with HIV-1 weighing at least 2 kg, expanding age-appropriate options from birth. FDA Oncology Breakthrough: The FDA also approved daraxonrasib (Rasonque) for previously treated metastatic pancreatic cancer, aiming to give patients a new targeted, oral option ahead of schedule. Cancer Care Optimization: A Dana-Farber-led adaptive planning trial targets stereotactic radiosurgery precision for brain metastases that shift between imaging and treatment. Affordability & Access: Michigan lawmakers introduced a Medicaid buy-in program (Basic Health Program-style) for working adults earning 138–200% of the federal poverty level. Medicare Shock for Seniors: Hawaii health leaders warn that Medicare Part D ends next year, with expected premium and out-of-pocket increases for about 77,000 beneficiaries. Employer Pressure: A Business Group on Health survey finds cancer is the top driver of healthcare spending for the fifth straight year, as employers project rising costs into 2027. Provider Network Changes: Lee Health will drop UnitedHealthcare as an in-network provider starting in 2027, urging patients to check coverage status. Workforce & Training: Loyola and Ochsner launched an Executive MBA partnership for clinical leaders to strengthen healthcare strategy and leadership while they keep working. Policy & Practice: The AMA urged CMS to withdraw a proposed 50% cut to same-day office visit payments, arguing the agency lacks support for such a large reduction.